Trials / Completed
CompletedNCT00093041
Zalutumumab in Head and Neck Cancer
An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Genmab · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zalutumumab | Weekly infusion |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2005-01-12
- Completion
- 2005-01-12
- First posted
- 2004-10-01
- Last updated
- 2023-06-28
- Results posted
- 2011-12-22
Locations
5 sites across 2 countries: Denmark, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00093041. Inclusion in this directory is not an endorsement.